Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of efgartigimod alfa injection in adults with primary immune thrombocytopenia
CTR20251513Phase 3Active
- Sponsor
- argenx
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Started Jun 2025; status: active.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20251513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251513.